Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics and Prognosis of Hemolytic Disease of the Newborn Caused by Irregular Antibodies: A 13-Year Retrospective Analysis.
Children (Basel)
November 2024
Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China.
Background/objectives: The clinical characteristics and outcomes of hemolytic disease of the newborn (HDN) caused by irregular antibodies remain unclear. Herein, we analyzed the clinical features and prognosis of HDN.
Methods: Children admitted to our institution between June 2009 and December 2022 with a definite diagnosis of HDN were evaluated.
An immuno-inflammatory profiling of asymptomatic individuals in a malaria endemic area in Uganda.
Acta Trop
December 2024
Department of Laboratory medicine, Lund University, Lund, Sweden; Clinical Chemistry and Pharmacology, Office for Medical Services, Region Skåne, Lund, Sweden. Electronic address:
Malaria caused by Plasmodium falciparum leads to the destruction of red blood cells (RBCs). A better understanding of how naturally immune individuals control infections should be valuable for future vaccine studies. Antibodies against RBCs and RBC surface antigens were measured together with different inflammatory markers in healthy adults living in a malaria endemic area of Uganda and compared to Swedish healthy adults.
View Article and Find Full Text PDFUse of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.
Pharmacoepidemiol Drug Saf
October 2024
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Article Synopsis
- * An analysis of national claims databases from 2003 to 2019 revealed that the use of omalizumab for children aged 6-11 did not change after a negative FDA review in 2009 but increased significantly after the FDA approved its use for that age group in 2016.
- * The findings suggest that while initial regulatory concerns did not deter drug use, the eventual approval led to a notable rise in omalizumab prescriptions for younger children, highlighting the need for better processes to expedite
[Efficacy of biologics for severe asthma on allergic comorbidities].
Rev Mal Respir
November 2024
Service de pneumologie et centre de référence des maladies pulmonaires rares, AP-HP Nord, hôpital Bichat, 75018 Paris, France; Inserm UMR1152, université Paris Cité, Paris, France.
Article Synopsis
- Some treatments called biologics can help people with severe asthma and other allergic diseases like skin issues and food allergies.
- Dupilumab has been shown to work well for skin problems and has been approved, while Omalizumab helps with allergies but isn't approved for that use yet.
- There are promising ideas about combining biologic therapy with other treatments for allergies, but more research is needed to confirm if they really work.
Rheumatic adverse events associated with biologic therapy for chronic rhinosinusitis: A systematic review and meta-analysis.
Int Forum Allergy Rhinol
October 2024
Division of Rhinology, Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Toronto, Ontario, Canada.
Background: Biologic therapies approved for treating chronic rhinosinusitis with nasal polyps (CRSwNP) have well-established safety profiles but reports of rheumatic adverse events (AEs) are increasing and not well defined. This review aims to assess the risk and incidence of rheumatic AEs associated with biologic therapy in CRSwNP and summarize current reported management strategies.
Methods: A protocol was registered in PROSPERO [CRD42024525663].
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!